KL340399

KL340399 is a small molecule STING (stimulator of interferon genes) agonist in clinical development for the treatment of advanced solid tumors. It acts by activating the intracellular innate immune adaptor protein STING (also known as TMEM173), which leads to immunoactivating and antineoplastic effects. Activation of the STING pathway induces production of type I interferons and proinflammatory cytokines, stimulating natural killer cells and T cells, thereby promoting anti-tumor immunity. KL340399 is being developed by Sichuan Kelun Pharmaceutical Research Institute and its affiliates, with ongoing phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[1][2][3][4][5].